SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

12 Feb 2025 Evaluate
Revenue reduced marginally to stand at Rs. 2173.43 millions during the quarter ended December 2024. The figure stood at Rs. 2205.91 millions during the year-ago period.The Net proft of the company remain more or less same to Rs. 239.07  millions from Rs. 305.45 millions ,decline by -21.73%.The Operating Profit of the company witnessed a decrease to 363.03 millions from 433.51 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 2173.43 2205.91 -1.47 6844.48 6022.66 13.65 8193.68 6658.98 23.05
Other Income 99.37 74.36 33.63 256.72 175.04 46.66 303.89 194.30 56.40
PBIDT 363.03 433.51 -16.26 1148.71 992.60 15.73 1410.70 1030.49 36.90
Interest 37.91 35.37 7.18 105.60 128.80 -18.01 163.28 322.26 -49.33
PBDT 325.12 398.14 -18.34 1043.11 863.80 20.76 1247.42 1100.33 13.37
Depreciation 86.05 92.69 -7.16 256.74 248.18 3.45 332.19 547.87 -39.37
PBT 239.07 305.45 -21.73 786.37 615.62 27.74 915.23 552.46 65.66
TAX 0.00 0.00 0.00 0.00 0.00 0.00 -32.26 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 -32.26 0.00 0.00
PAT 239.07 305.45 -21.73 786.37 615.62 27.74 947.49 552.46 71.50
Equity 507.19 507.19 0.00 507.19 507.19 0.00 507.19 408.16 24.26
PBIDTM(%) 16.70 19.65 -15.01 16.78 16.48 1.83 17.22 15.48 11.25

Orchid Pharma Share Price

544.95 -14.25 (-2.55%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×